Influence of volume medium on growth and ginsenoside level in adventitious root culture of Panax ginseng CA Meyer

Ginseng (Panax ginseng, Family Araliaceae) is a traditional herbal plant that is pretty well known and has been widely used in various countries, such as Korea, China, and Japan. Ginseng contains ginsenoside secondary metabolites that have been shown to have therapeutic effects, such as antioxidant, anti-inflammatory, anti-allergic, anti-diabetic, and anti-cancer. Ginseng production by traditional cultivation methods is long and produces inconsistent results. Therefore, in vitro culture is an alternative method to produce ginseng and ginsenoside consistently. In 2018, PT Bintang Todjoe collaborated with the University of Surabaya (UBAYA) and the Hanbang-Bio Inc. (holding company of Kyung Hee University) to establish the Kalbe Ubaya Hanbang-Bio Laboratory (KUH Lab). From previous studies, the dry weight achieved was only 109.758 g, which did not reach the target (120 grams). Therefore, the media was modified by adding media volume from 13L to 15L. The increase in media volume increased fresh weight to 2728.7 g, dry weight to 137.6 g, and yield up to 5%. However, this increase in media volume has not increased ginsenoside levels

Wound Healing Effectiveness Test of Dermal Patch Formulated with Green Synthesized Silver Nanoparticles from Plantago major L. Extract

Skin is the largest organ in the body and has a very important role. A wound is an injury in which the skin is torn, cut, punctured, or traumatized. Wounds in diabetic patients are difficult to heal. Green synthesis is one of many methods that can be used to synthesize silver nanoparticles. Based on a statistical analysis of the average wound area, epidermal reconstruction, and TIME-H scores, significant differences began to occur from day 12 to day 14. The average wound area, epidermal reconstruction, and TIME-H scores in the diabetic mice group that were given a dermal patch formulated with silver nanoparticles synthesized using Plantago major L. extract were not significantly different from the normal group and the ACA and ACA Ag groups. Based on these results, it can be concluded that the dermal patch formulated with silver nanoparticles synthesized using Plantago major L. extract helps wound healing in diabetic mice and is not significantly different from wound dressings and silver dressings on the market (p-value < 0.05). In addition, the best concentration that can be formulated into the dermal patch is 0.005% (p-value <0.05)

Mass Production of Panax ginseng C.A. Mey. Root Cultures in Indonesia

Panax ginseng C.A. Mey. is one of the most well-known plants in traditional medicine that contains bioactive compounds called ginsenosides. It is widely used as raw material in many pharmaceutical industries in Indonesia. However, to supply for this purpose, they still rely on imports. PT. Kalbe Farma (through its subsidiary, PT. Bintang Toedjoe), University of Surabaya (Ubaya), and Hanbang-Bio Laboratory (holding company of Kyung Hee University) established the Kalbe Ubaya Hanbang-Bio Laboratory (KUH Lab), a collaboration initiated to achieve the independence of raw materials. This laboratory is devoted to developing the plant tissue culture protocol for the mass production of P. ginseng root cultures. This paper is the first report of in vitro P. ginseng culture in Indonesia. The initial stage of the mass production focused on optimizing the culture conditions: inoculum weight (100 g, 150 g, 200 g), medium volume (12 L, 13 L, 14 L), medium formulation (“A”, “B”), and incubation temperature (15 °C to 20 °C and 21°C to 25 °C). Based on the biomass yield and ginsenosides content, it was concluded that the optimum growth condition was 150 g of the initial inoculum grown in 13 L of media using formulation B and incubation at 21°C to 25 °C. In the long-term, KUH Lab aims to produce P. ginseng on an industrial scale to sufficiently supply the demands for P. ginseng in the country. Furthermore, this laboratory also intends to make standardized Indonesian herbal materials by using plant tissue culture

The Effect of Elisitor on Growth and Ginsenoside Level in Hairy Root Culture of Panax ginseng Cultivated in Shake Flasks

In recent years, plants have become an important part of traditional medicine. Although the medicinal potential of the plant looks very promising, there are great difficulties that inhibit products for the production of herbs on a large scale. Panax ginseng C.A. Mey. is a plant often used in traditional medicine in various countries because ginseng can cure various diseases in humans. The main bioactive component in ginseng is the triterpene saponin compound, namely ginsenosides. Ginseng needs to be cultivated at least 4 yr before the root can be harvested. In addition, a special environment is needed for ginseng to develop properly. One way to obtain ginsenosides is to use root hair culture. However, until now it has been reported that the accumulation of ginsensoside in root hair cultures is still low. Elicitation effective method to increase the production of secondary metabolites in vitro culture. The aim of this research was to observe the effect of elicitor in the form of yeast extract and coconut water to the media on the growth and levels of ginsenoside in flask scale Panax ginseng root hair culture. From the data obtained, it can be concluded that the addition of yeast extract from the start with a concentration of 20 mg L–1 cannot increase the levels of ginsenoside in the hairy root culture of P. ginseng. The addition of coconut water from the beginning with a volume of 10 mL increases the biomass but cannot increase the ginsenoside levels in the hair culture of P. ginseng

Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021

BackgroundEstimates of demographic metrics are crucial to assess levels and trends of population health outcomes. The profound impact of the COVID-19 pandemic on populations worldwide has underscored the need for timely estimates to understand this unprecedented event within the context of long-term population health trends. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 provides new demographic estimates for 204 countries and territories and 811 additional subnational locations from 1950 to 2021, with a particular emphasis on changes in mortality and life expectancy that occurred during the 2020–21 COVID-19 pandemic period.Methods22 223 data sources from vital registration, sample registration, surveys, censuses, and other sources were used to estimate mortality, with a subset of these sources used exclusively to estimate excess mortality due to the COVID-19 pandemic. 2026 data sources were used for population estimation. Additional sources were used to estimate migration; the effects of the HIV epidemic; and demographic discontinuities due to conflicts, famines, natural disasters, and pandemics, which are used as inputs for estimating mortality and population. Spatiotemporal Gaussian process regression (ST-GPR) was used to generate under-5 mortality rates, which synthesised 30 763 location-years of vital registration and sample registration data, 1365 surveys and censuses, and 80 other sources. ST-GPR was also used to estimate adult mortality (between ages 15 and 59 years) based on information from 31 642 location-years of vital registration and sample registration data, 355 surveys and censuses, and 24 other sources. Estimates of child and adult mortality rates were then used to generate life tables with a relational model life table system. For countries with large HIV epidemics, life tables were adjusted using independent estimates of HIV-specific mortality generated via an epidemiological analysis of HIV prevalence surveys, antenatal clinic serosurveillance, and other data sources. Excess mortality due to the COVID-19 pandemic in 2020 and 2021 was determined by subtracting observed all-cause mortality (adjusted for late registration and mortality anomalies) from the mortality expected in the absence of the pandemic. Expected mortality was calculated based on historical trends using an ensemble of models. In location-years where all-cause mortality data were unavailable, we estimated excess mortality rates using a regression model with covariates pertaining to the pandemic. Population size was computed using a Bayesian hierarchical cohort component model. Life expectancy was calculated using age-specific mortality rates and standard demographic methods. Uncertainty intervals (UIs) were calculated for every metric using the 25th and 975th ordered values from a 1000-draw posterior distribution.FindingsGlobal all-cause mortality followed two distinct patterns over the study period: age-standardised mortality rates declined between 1950 and 2019 (a 62·8% [95% UI 60·5–65·1] decline), and increased during the COVID-19 pandemic period (2020–21; 5·1% [0·9–9·6] increase). In contrast with the overall reverse in mortality trends during the pandemic period, child mortality continued to decline, with 4·66 million (3·98–5·50) global deaths in children younger than 5 years in 2021 compared with 5·21 million (4·50–6·01) in 2019. An estimated 131 million (126–137) people died globally from all causes in 2020 and 2021 combined, of which 15·9 million (14·7–17·2) were due to the COVID-19 pandemic (measured by excess mortality, which includes deaths directly due to SARS-CoV-2 infection and those indirectly due to other social, economic, or behavioural changes associated with the pandemic). Excess mortality rates exceeded 150 deaths per 100 000 population during at least one year of the pandemic in 80 countries and territories, whereas 20 nations had a negative excess mortality rate in 2020 or 2021, indicating that all-cause mortality in these countries was lower during the pandemic than expected based on historical trends. Between 1950 and 2021, global life expectancy at birth increased by 22·7 years (20·8–24·8), from 49·0 years (46·7–51·3) to 71·7 years (70·9–72·5). Global life expectancy at birth declined by 1·6 years (1·0–2·2) between 2019 and 2021, reversing historical trends. An increase in life expectancy was only observed in 32 (15·7%) of 204 countries and territories between 2019 and 2021. The global population reached 7·89 billion (7·67–8·13) people in 2021, by which time 56 of 204 countries and territories had peaked and subsequently populations have declined. The largest proportion of population growth between 2020 and 2021 was in sub-Saharan Africa (39·5% [28·4–52·7]) and south Asia (26·3% [9·0–44·7]). From 2000 to 2021, the ratio of the population aged 65 years and older to the population aged younger than 15 years increased in 188 (92·2%) of 204 nations.InterpretationGlobal adult mortality rates markedly increased during the COVID-19 pandemic in 2020 and 2021, reversing past decreasing trends, while child mortality rates continued to decline, albeit more slowly than in earlier years. Although COVID-19 had a substantial impact on many demographic indicators during the first 2 years of the pandemic, overall global health progress over the 72 years evaluated has been profound, with considerable improvements in mortality and life expectancy. Additionally, we observed a deceleration of global population growth since 2017, despite steady or increasing growth in lower-income countries, combined with a continued global shift of population age structures towards older ages. These demographic changes will likely present future challenges to health systems, economies, and societies. The comprehensive demographic estimates reported here will enable researchers, policy makers, health practitioners, and other key stakeholders to better understand and address the profound changes that have occurred in the global health landscape following the first 2 years of the COVID-19 pandemic, and longer-term trends beyond the pandemic